Intel stock extends gains after report of possible U.S. government stake
BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company with a market capitalization of $462 million and strong liquidity position, announced Tuesday the launch of an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock. According to InvestingPro data, the company maintains more cash than debt on its balance sheet, with a healthy current ratio of 7.66.
The clinical-stage oncology-focused biopharmaceutical company plans to offer all shares and pre-funded warrants through the company itself, with no shares being sold by existing shareholders. The stock has shown remarkable performance, gaining over 130% year-to-date and nearly 196% over the past year. Compass also intends to grant underwriters a 30-day option to purchase additional shares under the same terms.
Jefferies, Piper Sandler and Guggenheim Securities are serving as joint active bookrunning managers for the offering, according to the company’s press release statement.
The company plans to use proceeds from the offering to prepare for commercial readiness, fund research and clinical development of its product candidates, and for general corporate purposes. Analysts maintain a bullish outlook on CMPX, with price targets ranging from $7 to $32 per share. For deeper insights into Compass Therapeutics’ financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
The offering is subject to market conditions, with no guarantee regarding completion timing or final terms. It will be made through a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on August 30, 2024, which was declared effective on September 6, 2024.
Compass Therapeutics focuses on developing antibody-based therapeutics targeting the relationship between angiogenesis, the immune system, and tumor growth. The company, founded in 2014 and headquartered in Boston, is advancing product candidates as both standalone therapies and in combination with proprietary pipeline antibodies.
In other recent news, Compass Therapeutics reported its second-quarter 2025 financial results, highlighting a net loss of $19.9 million and earnings per share of -$0.14. This was a wider loss than analysts had forecasted, with expectations set at -$0.12 per share. Despite this earnings miss, the company maintains a strong cash position with approximately $101 million, which is anticipated to support operations through 2027. Guggenheim responded by raising its price target for Compass Therapeutics from $10.00 to $12.00, maintaining a Buy rating, following the company’s promising clinical data and updates. The company announced a revised timeline for the final analysis of its COMPANION-002 Phase 2/3 trial, now expected in the first quarter of 2026. Raymond James also maintained its Outperform rating with a $9.00 price target, citing the company’s financial results and ongoing clinical trials. These updates reflect ongoing developments in Compass Therapeutics’ financial and clinical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.